Passage BIO, Inc.

Listed Company

PASGCIK 0001787297NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-45.52M

Total Assets

$62.28M

Equity

$18.75M

Shares Out

3.21M

Op. Cash Flow

$-31.51M

PASG$4.87−15.24% · past yearDBEQ Basic

Daily closing prices

Business

Passage Bio is a clinical-stage genetic medicines company developing one-time gene therapies for neurodegenerative diseases. The company's lead candidate, PBFT02, is an AAV1-based gene replacement therapy designed to elevate progranulin levels and is currently in Phase 1/2 clinical trials for frontotemporal dementia caused by progranulin deficiency, with expansion into additional indications including FTD-C9orf72 and ALS. The company also maintains a preclinical research program for Huntington's disease through a collaboration with Gemma Biotherapeutics and has outlicensed pediatric programs to Gemma.

Summary from 10-K filed 2026-03-03

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	23	40	61	—	—
General and administrative	20	25	42	49	60
Impairment of long-lived assets	6	5	5	—	—
Loss from operations	−49	−70	−108	−138	−186
Other income (expense), net	4	6	6	2	—
Net loss	−46	−65	−102	−136	−185
Net loss per share of common stock, basic	−14.35	−21.04	−1.86	−2.5	−3.48
Net loss per share of common stock, diluted	−14.35	−21.04	−1.86	−2.5	−3.48
Weighted average common shares outstanding, basic	3	3	55	54	53
Weighted average common shares outstanding, diluted	3	3	55	54	53
Unrealized gain (loss) on marketable securities	−8,000	51,000	923,000	−553,000	−401,000
Comprehensive loss	−46	−65	−101	−137	−186

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	46	38	22	35	129
Marketable securities	0	39	93	155	187
Prepaid expenses and other current assets	629,000	838,000	923,000	926,000	2
Prepaid research and development	830,000	1	3	7	8
Total current assets	48	79	118	197	325
Property and equipment, net	4	9	15	23	24
Right of use assets - operating leases	10	14	17	20	—
Other assets	244,000	463,000	433,000	4	6
Total assets	62	102	151	244	355
Accounts payable	1	742,000	1	4	9
Accrued expenses and other current liabilities	5	7	12	11	20
Non-refundable sublicense and transition services payments	14	8	—	—	—
Operating lease liabilities	4	4	3	3	—
Total current liabilities	23	19	16	18	29
Operating lease liabilities - noncurrent	20	22	23	24	—
Total liabilities	44	41	39	42	36
Commitments and contingencies (note 11)	—	—	—	—	—
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both December 31, 2025 and December 31, 2024	—	—	—	—	—
Additional paidin capital	724	720	706	695	675
Accumulated other comprehensive income (loss)	—	8,000	−43,000	−966,000	−413,000
Accumulated deficit	−705	−659	−594	−492	−356
Total stockholders' equity	19	61	111	201	319
Total liabilities and stockholders' equity	62	102	151	244	355

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	700,000	3	4	4	2
Sharebased compensation	3	6	11	19	33
Amortization of premium and discount on marketable securities, net	129,000	−2	−2	773,000	3
Other non-cash items	14,000	—	—	—	—
Prepaid expenses and other current assets, and other assets	228,000	255,000	4	3	2
Prepaid research and development	391,000	2	4	1	3
Non-refundable sublicense and transition services payments received	4	8	—	—	—
Right of use assets and operating lease liabilities	−464,000	−279,000	−133,000	463,000	—
Accounts payable	2	−556,000	−3	−5	2
Accrued expenses and other current liabilities	−2	−5	659,000	−7	—
Net cash provided by (used in) operating activities	−32	−48	−78	−118	−127
Purchases of marketable securities	—	−88	−129	−158	−203
Sales or maturities of marketable securities	39	143	195	188	182
Purchases of property and equipment and other assets	—	−34,000	—	—	—
Sales of property and equipment and other assets	1	—	—	—	—
Net cash provided by (used in) investing activities	40	55	65	25	−46
Proceeds from issuance of common stock under the ATM Facility, net of offering costs	—	9	—	—	—
Proceeds from the exercise of stock options	—	35,000	—	129,000	301,000
Proceeds from the issuance of common stock under employee stock purchase plan	23,000	97,000	135,000	304,000	887,000
Net cash provided by (used in) financing activities	23,000	9	135,000	−1	167
Net increase (decrease) in cash and cash equivalents	9	16	−13	−94	−6
Unrealized gain (loss) on marketable securities	−8,000	51,000	923,000	−553,000	−401,000
Right of use assets recognized upon the commencement of sublease	—	−422,000	—	−20	—
Operating lease liabilities recognized upon the commencement of sublease	—	422,000	—	27	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Passage BIO, Inc.'s CIK number?

Passage BIO, Inc.'s SEC CIK number is 0001787297 (1787297). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Passage BIO, Inc.'s SEC filings?

All of Passage BIO, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Passage BIO, Inc. last report earnings?

Passage BIO, Inc. (PASG) most recently filed an earnings 8-K with the SEC on Mar 3, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-022539). This is Passage BIO, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Passage BIO, Inc.'s most recent earnings 8-K?

Passage BIO, Inc.'s latest earnings 8-K (Item 2.02) was filed Mar 3, 2026 under accession 0001104659-26-022539. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Passage BIO, Inc.'s latest earnings 8-K →
Look up any company's CIK number →